Movement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation

Market Focus09-30 10:05

On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital Group Companies, one of the world's largest asset management firms.

According to filings with the Hong Kong Stock Exchange, Capital Group purchased 1.9494 million shares of BEONE MEDICINES on September 24 at an average price of USD 358.77 per share, investing approximately USD 699 million. This followed an earlier purchase on September 9 of 3.0704 million shares at an average price of USD 348.48, totaling roughly USD 1.07 billion. Combined, the two transactions exceed USD 1.7 billion, lifting Capital Group's stake from 6.97% to 8.08%.

The institutional accumulation comes on the heels of strong half-year results, with revenue rising 32.3% year-over-year to USD 3.219 billion and adjusted net profit surging 111% to USD 820 million. The flagship product Brukinsa generated USD 2.342 billion in global sales, accounting for 74% of product revenue. Multiple brokerages maintain a Buy rating, with CLSA naming BEONE MEDICINES as a top pick in China biotech.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140261443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140261443","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation","media":"Market Focus","content":"<p><p>On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital Group Companies, one of the world's largest asset management firms.</p><p>According to filings with the Hong Kong Stock Exchange, Capital Group purchased 1.9494 million shares of BEONE MEDICINES on September 24 at an average price of USD 358.77 per share, investing approximately USD 699 million. This followed an earlier purchase on September 9 of 3.0704 million shares at an average price of USD 348.48, totaling roughly USD 1.07 billion. Combined, the two transactions exceed USD 1.7 billion, lifting Capital Group's stake from 6.97% to 8.08%.</p><p>The institutional accumulation comes on the heels of strong half-year results, with revenue rising 32.3% year-over-year to USD 3.219 billion and adjusted net profit surging 111% to USD 820 million. The flagship product Brukinsa generated USD 2.342 billion in global sales, accounting for 74% of product revenue. Multiple brokerages maintain a Buy rating, with CLSA naming BEONE MEDICINES as a top pick in China biotech.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-30 10:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital Group Companies, one of the world's largest asset management firms.</p><p>According to filings with the Hong Kong Stock Exchange, Capital Group purchased 1.9494 million shares of BEONE MEDICINES on September 24 at an average price of USD 358.77 per share, investing approximately USD 699 million. This followed an earlier purchase on September 9 of 3.0704 million shares at an average price of USD 348.48, totaling roughly USD 1.07 billion. Combined, the two transactions exceed USD 1.7 billion, lifting Capital Group's stake from 6.97% to 8.08%.</p><p>The institutional accumulation comes on the heels of strong half-year results, with revenue rising 32.3% year-over-year to USD 3.219 billion and adjusted net profit surging 111% to USD 820 million. The flagship product Brukinsa generated USD 2.342 billion in global sales, accounting for 74% of product revenue. Multiple brokerages maintain a Buy rating, with CLSA naming BEONE MEDICINES as a top pick in China biotech.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1140261443","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140261443","pubTimestamp":1790733941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势预警|BEONE MEDICINES常规交易上涨3.03%，全球资产管理公司资本集团继续大规模累积","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital Group Companies, one of the world's largest asset management firms.According to filings with the Hong Kong Stock Exchange, Capital Group purchased 1.9494 million shares of BEONE MEDICINES on September 24 at an average price of USD 358.77 per share, investing approximately USD 699 million. This followed an earlier purchase on September 9 of 3.0704 million shares at an average price of USD 348.48, totaling roughly USD 1.07 billion. Combined, the two transactions exceed USD 1.7 billion, lifting Capital Group's stake from 6.97% to 8.08%.The institutional accumulation comes on the heels of strong half-year results, with revenue rising 32.3% year-over-year to USD 3.219 billion and adjusted net profit surging 111% to USD 820 million. The flagship product Brukinsa generated USD 2.342 billion in global sales, accounting for 74% of product revenue. Multiple brokerages maintain a Buy rating, with CLSA naming BEONE MEDICINES as a top pick in China biotech.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140261443","isCrawlerRequest":true}